Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea.
Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TNMI7-0024-2016.
Nontuberculous mycobacteria (NTM) are emerging pathogens that affect both immunocompromised and immunocompetent patients. The development of molecular methods has allowed the characterization of new species and the identification of NTM to the precise species and subspecies levels. The incidence and prevalence of NTM lung disease are increasing worldwide, and this syndrome accounts for the majority of clinical cases of NTM disease. Common causative organisms of pulmonary infection are the slowly growing mycobacteria Mycobacterium avium complex and Mycobacterium kansasii and the rapidly growing mycobacteria, including Mycobacterium abscessus complex. NTM lung disease often affects elderly people with chronic lung disease and may be a manifestation of a complex genetic disorder determined by interactions among multiple genes, as well as environmental exposures. To be diagnosed with NTM lung disease, patients should meet all clinical and microbiologic criteria, but the decision to start treatment is complex, requiring careful individualized analysis of risks and benefits. Clinicians should be alert to the unique aspects of NTM lung disease, including the need for proper diagnosis, the availability of advanced molecular methods for species and subspecies identification, and the benefits and limitations of recommended treatments.
非结核分枝杆菌(NTM)是新兴的病原体,影响免疫功能低下和免疫功能正常的患者。分子方法的发展使得能够对新物种进行特征描述,并将 NTM 准确鉴定到种和亚种水平。全球范围内 NTM 肺病的发病率和患病率正在增加,该综合征占 NTM 疾病的大多数临床病例。肺部感染的常见病原体是生长缓慢的分枝杆菌,包括鸟分枝杆菌复合群和堪萨斯分枝杆菌,以及生长迅速的分枝杆菌,包括脓肿分枝杆菌复合群。NTM 肺病常发生于患有慢性肺病的老年人,可能是由多个基因相互作用以及环境暴露决定的复杂遗传疾病的表现。要诊断为 NTM 肺病,患者应符合所有临床和微生物学标准,但开始治疗的决定很复杂,需要仔细分析风险和收益。临床医生应注意 NTM 肺病的独特方面,包括正确诊断的必要性、用于种和亚种鉴定的先进分子方法的可用性,以及推荐治疗的益处和局限性。